Here's a thinking process:
1. **Analyze User Input:**
- **Role:** Frank, excited, passionate tech-savvy news curator on Evil Source forums.
- **Task:** Rewrite the provided article into a FULL, in-depth forum post.
- **Critical Rules:**
- Write 1 to 3 PARAGRAPHS exactly.
- Each paragraph: 4-8 sentences forming a complete thought. Never less than 4.
- Include EVERY detail, fact, insight from the article.
- Exciting, casual, direct forum style.
- Add own commentary, opinions, reactions throughout.
- Include ALL key information: who, what, when, where, why, how, specs, prices, dates.
- Use line breaks between paragraphs.
- End with: 'Source: <original URL>'
- If additional sources, add: 'Also see: <url1>, <url2>'
- Make it the DEFINITIVE version.
- NEVER write less than one full paragraph.
- **Source Article:** Ars Technica article by Beth Mole, June 17, 2026. About FDA clearing a second fly species (*Lucilia cuprina*) for maggot wound therapy, held by Cuprina Holdings (Singapore-based). CEO David Quek, Medical/Scientific Director Ronald Sherman. Mentions *L. sericata* cleared in 2004. Mechanism: enzymes liquify necrotic tissue, consume slurry, antibacterial compounds, prevent biofilms, stimulate tissue regrowth. Niche due to lack of robust trials, "ick factor," coincides with New World screwworm invasion in US. Accidental myiasis cases in 2018 Chicago report showed benefits, also flagged undiagnosed cancers. Bacon therapy for extraction in California. Claims evidence supports infection prevention and tissue growth stimulation. Source URL provided.
2. **Deconstruct Source for Key Details:**
- **Who:** Cuprina Holdings (Singapore-based), CEO David Quek, Medical/Scientific Director Ronald Sherman, Beth Mole (Ars Technica reporter), researchers in Chicago & California.
- **What:** FDA cleared second carcass-eating fly species (*Lucilia cuprina*, Australian sheep blowfly) for maggot wound therapy (MDT/biosurgery). Cuprina now holds clearance for both species (*L. sericata* cleared in 2004).
- **When:** June 17, 2026 (article date). FDA clearance announced "this week."
- **Where:** Singapore-based company, US FDA clearance, international markets (Australia, Africa, Asia, Americas for *L. cuprina*; Western markets for *L. sericata*).
- **Why/How:** Maggots secrete enzymes to liquify necrotic tissue, consume slurry from nooks/crannies, secrete antibacterial compounds, block biofilms, prevent secondary infection, stimulate tissue regrowth. Less painful/more efficient than surgical debridement for chronic wounds like diabetic ulcers.
- **Context/Challenges:** "Ick factor," lack of robust trials/evidence, remains niche/last resort. Coincides with New World screwworm invasion in US. *Lucilia* species aren't parasitic (mainly carrion), though *L. cuprina* can cause flystrike in sheep.
- **Fun/Extra Details:** Rebranding attempts ("wee walruses", "maggies"), 2018 Chicago accidental myiasis report showing benefits & flagging undiagnosed cancers, California "bacon therapy" for extraction (5-10 mins, mechanism unknown but works).
- **Quotes:** Quek: "defensible edge", Sherman: "earned its place in modern wound care".
3. **Draft - Paragraph 1: The Announcement & The Science (Focus on excitement, key facts, mechanism)**
*Need 4-8 sentences. Must include: FDA clearance, Cuprina Holdings, both species, *L. cuprina* vs *L. sericata*, 2004 clearance, Sherman/Quek roles, mechanism of action, diabetic ulcers, enzymes, antibacterial, biofilm prevention, tissue regrowth.*
Let's craft it carefully to hit 4-8 sentences while packing in details and Frank's excitement.
*Draft P1:*
Okay, tech and biohacking nerds, buckle up because the FDA just dropped some genuinely wild news this week—Cuprina Holdings, a Singapore-based biotech outfit, has officially cleared a second carcass-eating fly species for medical use, and honestly, I am absolutely living for this! They’ve now secured FDA clearance for *Lucilia cuprina*,
1. **Analyze User Input:**
- **Role:** Frank, excited, passionate tech-savvy news curator on Evil Source forums.
- **Task:** Rewrite the provided article into a FULL, in-depth forum post.
- **Critical Rules:**
- Write 1 to 3 PARAGRAPHS exactly.
- Each paragraph: 4-8 sentences forming a complete thought. Never less than 4.
- Include EVERY detail, fact, insight from the article.
- Exciting, casual, direct forum style.
- Add own commentary, opinions, reactions throughout.
- Include ALL key information: who, what, when, where, why, how, specs, prices, dates.
- Use line breaks between paragraphs.
- End with: 'Source: <original URL>'
- If additional sources, add: 'Also see: <url1>, <url2>'
- Make it the DEFINITIVE version.
- NEVER write less than one full paragraph.
- **Source Article:** Ars Technica article by Beth Mole, June 17, 2026. About FDA clearing a second fly species (*Lucilia cuprina*) for maggot wound therapy, held by Cuprina Holdings (Singapore-based). CEO David Quek, Medical/Scientific Director Ronald Sherman. Mentions *L. sericata* cleared in 2004. Mechanism: enzymes liquify necrotic tissue, consume slurry, antibacterial compounds, prevent biofilms, stimulate tissue regrowth. Niche due to lack of robust trials, "ick factor," coincides with New World screwworm invasion in US. Accidental myiasis cases in 2018 Chicago report showed benefits, also flagged undiagnosed cancers. Bacon therapy for extraction in California. Claims evidence supports infection prevention and tissue growth stimulation. Source URL provided.
2. **Deconstruct Source for Key Details:**
- **Who:** Cuprina Holdings (Singapore-based), CEO David Quek, Medical/Scientific Director Ronald Sherman, Beth Mole (Ars Technica reporter), researchers in Chicago & California.
- **What:** FDA cleared second carcass-eating fly species (*Lucilia cuprina*, Australian sheep blowfly) for maggot wound therapy (MDT/biosurgery). Cuprina now holds clearance for both species (*L. sericata* cleared in 2004).
- **When:** June 17, 2026 (article date). FDA clearance announced "this week."
- **Where:** Singapore-based company, US FDA clearance, international markets (Australia, Africa, Asia, Americas for *L. cuprina*; Western markets for *L. sericata*).
- **Why/How:** Maggots secrete enzymes to liquify necrotic tissue, consume slurry from nooks/crannies, secrete antibacterial compounds, block biofilms, prevent secondary infection, stimulate tissue regrowth. Less painful/more efficient than surgical debridement for chronic wounds like diabetic ulcers.
- **Context/Challenges:** "Ick factor," lack of robust trials/evidence, remains niche/last resort. Coincides with New World screwworm invasion in US. *Lucilia* species aren't parasitic (mainly carrion), though *L. cuprina* can cause flystrike in sheep.
- **Fun/Extra Details:** Rebranding attempts ("wee walruses", "maggies"), 2018 Chicago accidental myiasis report showing benefits & flagging undiagnosed cancers, California "bacon therapy" for extraction (5-10 mins, mechanism unknown but works).
- **Quotes:** Quek: "defensible edge", Sherman: "earned its place in modern wound care".
3. **Draft - Paragraph 1: The Announcement & The Science (Focus on excitement, key facts, mechanism)**
*Need 4-8 sentences. Must include: FDA clearance, Cuprina Holdings, both species, *L. cuprina* vs *L. sericata*, 2004 clearance, Sherman/Quek roles, mechanism of action, diabetic ulcers, enzymes, antibacterial, biofilm prevention, tissue regrowth.*
Let's craft it carefully to hit 4-8 sentences while packing in details and Frank's excitement.
*Draft P1:*
Okay, tech and biohacking nerds, buckle up because the FDA just dropped some genuinely wild news this week—Cuprina Holdings, a Singapore-based biotech outfit, has officially cleared a second carcass-eating fly species for medical use, and honestly, I am absolutely living for this! They’ve now secured FDA clearance for *Lucilia cuprina*,